Ireland: Weed is Messing Up Kids & Family’s – Time to EDUCATE

Why marijuana remains a highly risky habit that can ravage young people’s lives

Kathy Donaghy June 10 2018

Any debate around the legalisation of cannabis must take into account the harm it causes, one of the country’s leading psychiatrists has warned.

Consultant psychiatrist Dr Matthew Sadlier is calling for a public health campaign to educate people about the dangers of cannabis use.

As attitudes to cannabis use become more relaxed and tolerance increases in society in general, Dr Sadlier says many young people’s lives are being wrecked by habitual use of the drug – and that this side of the story is not being heard.

In his work as a general adult psychiatrist in north Dublin over the last five years, he says he could comfortably say that a third of all his patients had been referred because of cannabis.

“There are people out there who have developed long-term psychotic illnesses from smoking cannabis. If they’d never smoked it, they would never have developed it. We know that acute usage causes neurological conditions. The question is does it have a long-term effect?

“We know that the younger you start smoking it, the more likely it is to have a lasting, damaging effect. What gets my blood boiling is that it’s also carcinogenic. We have spent 40 years getting cigarette smoking down, but smoking cannabis has the same negative effects as cigarette smoking,” says Dr Sadlier.

“I think there has to be a public health campaign because the information out there for young people is very confused. We have people speaking up for the medicinal effects. Street cannabis is a very different thing and it’s very dangerous,” he says.

“I have seen families ripped apart by cannabis use. I’ve seen people with good futures ahead of them fall into apathy due to chronic cannabis use. People need to be educated about this. In my opinion, it’s much more dangerous than alcohol,” says Dr Sadlier.

For complete article https://www.independent.ie/irish-news/why-marijuana-remains-a-highly-risky-habit-that-can-ravage-young-peoples-lives-36987969.html

 

Posted in Uncategorized | Leave a comment

USA: Marijuana Pain Management a Myth??

Dr. Sanjay Gupta misleads: No evidence marijuana helps curb opioid addiction

by Kenneth Finn, M.D. | May 08, 2018

I have been practicing pain medicine in Colorado for 24 years and I have seen patients referred to me on very high-dose opioids, reporting very high levels of pain, and using marijuana for pain control. In discussions with these patients, and overall, more than 95 percent report that their use of marijuana does not help with their presenting pain symptoms.

In my clinical practice in Colorado, patients openly report sharing their medical marijuana and growing their own marijuana after their marijuana card expires. Now, with a legal layer of marijuana, people are self-diagnosing and treating their medical conditions without physician supervision.

Among drug-testing patients who are on chronic opioid therapy, it’s been my experience that those who independently (and without my knowledge) co-treat with marijuana tend to be positive for other illicit substances, which is consistent with the literature.

As it relates to the use of marijuana for pain, there is some evidence that there are components of the plant that may help in different pain conditions. It is important to understand the current evidence on pain involves only about 2,500 patients — few studies of short duration and not placebo-controlled. A National Academies of Science, Engineering and Medicine report misleadingly stated that “there is substantial evidence that cannabis is an effective treatment for chronic pain in adults.” But pain is a broad diagnosis and different types of pain will respond to different kinds of medications..

Currently there is no available accepted medical literature showing any benefit with dispensary cannabis in common pain conditions. This was noted in the Annals of Internal Medicine in August 2017.

As it relates to curbing the opioid epidemic, marijuana simply isn’t doing any such thing. The Colorado Department of Public Health and Environment has been monitoring this data over time, and 2017 was a record year for opioid deaths. The Journal of Public Health reported that opioid overdose deaths were on the decline, but did not take several things into consideration, such as lives saved through the newly widespread use of Narcan, physicians less likely to prescribe opioids, and patients becoming more reluctant to accept opioids. This also took place during a period of time when prescriptions were moving to long acting agents and abuse deterrent formulation.

Over time, opioid overdoses have continued to climb in Colorado, despite its 17-year-old medical marijuana program. Of greater concern in Colorado, the opioid epidemic has been morphing into a more widespread problem even as methamphetamine and cocaine are making a comeback. All together, this is increasing drug deaths in Colorado. I would be brave enough to suggest that yes, marijuana is a companion drug rather than a substitute, and it might even be contributing to the opioid epidemic in Colorado.

The American Journal of Psychiatry released a paper September 2017 following 33,000 people and showed that cannabis use “appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.” Regarding the association between cannabis use and aberrant behavior during chronic opioid therapy for chronic pain, it has been shown that patients using cannabis and opioid concurrently have a higher risk of opioid misuse.

Additionally, Evidence Based Practice found and published in January 2017 a piece showing that people using cannabis for pain were more likely — not less — to meet criteria for substance use disorders, and more likely to be noncompliant with their prescription opioids. Even patients in with chronic pain in an interdisciplinary pain rehabilitation program may be at higher risk for substance-related negative outcomes and are more likely to report a past history of illicit substance use, alcohol use, and tobacco use.

The upshot? There is no scientific evidence at all that marijuana use is helping the opioid epidemic, and quite a bit of evidence that it is actually contributing to the opioid epidemic.

Dr. Kenneth Finn is board certified in physical medicine and rehabilitation, pain medicine and pain management. He is a member of the American Academy of Physical Medicine and Rehabilitation, the American Academy of Pain Medicine, and the American Board of Pain Medicine, and an exam council member of the American Board of Pain Medicine.

https://www.washingtonexaminer.com/opinion/op-eds/dr-sanjay-gupta-misleads-no-evidence-marijuana-helps-curb-opioid-addiction

 

Posted in Uncategorized | Leave a comment

New York: Majority Don’t Want Weed!

For Immediate Release June 26, 2018
Contact: Colton Grace Colton@learnaboutsam.org
864-492-6719
More Than Half of New Yorkers Oppose Marijuana Legalization, According to New Emerson College Poll

More Than Three Quarters of African-American and Latino Respondents Did Not Support Marijuana Legalization
(New York, NY) – Today, Smart Approaches to Marijuana (SAM) and its New York Affiliate, SAM-NY,  released the results of a new Emerson College poll finding that the majority of New Yorkers do not support the legalization of marijuana. A plurality support either decriminalization or the current policy.
The poll, conducted by Emerson College — the same college that recently conducted a poll for pro-marijuana groups Marijuana Policy Project (MPP) and the Drug Policy Alliance (DPA) — found that 56% of respondents favored either keeping the current policy in New York, repealing decriminalization, were unsure, or were in favor or reinstating full criminalization.
A previous New York poll commissioned by pro-marijuana legalization groups pushed the false dichotomy of there only being two options in marijuana policy — full legalization or full prohibition. When respondents are informed of current marijuana laws (legal for medical use and decriminalized) support for legalization drops 27% from those polls.
The poll also found that 76% of New Yorkers did not  support marijuana advertising,  73% did not support public use of marijuana, 58% did not support marijuana stores in their neighborhoods, and half of New Yorkers were against marijuana candies, gummies, cookies, and other edibles.
Finally, the poll found that minority communities  overwhelmingly  opposed the full legalization of marijuana. Only 22% and 24% of Latinos and African Americans, respectively, supported legalization.
“New Yorkers do not support pot legalization. This poll shows us that elected officials need to slow down,” said Dr. Kevin Sabet, founder and president of SAM Action. “This poll shows similar results to our poll of New York voters in December–legalization is far from a slam dunk . One of the crucial takeaways from this is that minority communities are firmly opposed to legalization. And they should be — pot arrests for African American and Latino youth have gone up since legalization in Colorado. Pot Shops are always predominately in lower income neighborhoods.”
###
About SAM New York
SAM-NY, a project of SAM Action, is a nonpartisan alliance of lawmakers, scientists and other concerned citizens of New York dedicated to responsible marijuana policy that does not include the legalization of addictive substances. Learn more and join us at www.sam-ny.org.

 

Posted in Uncategorized | Leave a comment

USA: Proactive Pharmacovigilance

The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance

In response to the opioid crisis, the Food and Drug Administration (FDA) has taken action on multiple fronts. We have approved better measures for treating opioid use disorder and preventing deaths from overdose, have launched efforts to inform more appropriate prescribing as a way to limit clinical exposure to opioids, have taken actions to reduce the excess opioids available for abuse, and are working to facilitate development of new therapeutics that can effectively and safely help patients suffering from pain. Going forward, the FDA needs to remain vigilant to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow us to intervene promptly and appropriately and protect the public from associated risks.

Meanwhile, we must be aware that any decisive actions taken to reduce prescription opioid abuse and stem the tide of overdose and death can have unintended consequences, including prompting people to turn to alternative, potentially dangerous substances. In addition, as clinicians seek to help patients with pain, new prescribing patterns will emerge. Deciding on a course of action that will sustain appropriate use of prescription drugs while curtailing drug abuse is essential. Our assessment of changing patterns in drug use and abuse must be informed by an understanding of the complex social environment in which changing patterns of drug consumption occur. The FDA is committed to using a multicomponent system of pharmacovigilance so that we can intervene proactively and effectively, in anticipation of changes in drug abuse. Three recent examples illustrate the necessary elements of this system, which draws on clinical, epidemiologic, basic science, and social science expertise.

To begin with, an effective system of pharmacovigilance for drugs such as opioids must include the capacity to determine the reasons behind changing patterns of prescription-drug use and to elucidate the dynamics of misuse, abuse, and appropriate changes in prescribing. For example, the gabapentinoids (gabapentin and pregabalin) are approved for the treatment of seizures and certain forms of neuropathic pain. But U.S. rates of gabapentinoid use tripled between 2002 and 2015,1 and pregabalin ranked as one of the 10 best-selling drugs in 2017.2Increased prescription rates have raised concerns about possible abuse of gabapentinoids,3although their appropriate use for pain, alone or in combination with opioids and other medicines, complicates the matter.

To understand why usage patterns are shifting, the FDA used a social media “listening platform” to set up a dashboard to track traditional social media sites (such as Twitter, Facebook, Instagram, blogs, and forums) that we monitor for conversations about opioids. When we find mention of additional substances on social media or elsewhere, we conduct more specific searches for relevant, publicly available conversations through our listening platform, as well as through Reddit, Google, and various online forums that don’t require registration or subscription. These may include forums associated with drug misuse or abuse, such as Bluelight.org and talk.drugabuse.com. A preliminary appraisal of social media topics revealed a shift between 2013 and 2017 from a discussion of legitimate gabapentinoid use for pain and seizures to a focus on misuse and abuse of these drugs.

We are also exploring health care databases to assess the consequences of using gabapentinoids in combination with opioids. For example, the FDA Adverse Event Reporting System allows us to explore reports of respiratory depression (sometimes fatal) that may occur in association with use of these products in combination with other central nervous system depressants, including opioids. Additional epidemiologic data will help us understand the potential risks associated with the use of gabapentinoids concomitantly with opioids, benzodiazepines, and other drug products. Our preliminary epidemiologic assessments suggest that the number of patients to whom gabapentinoids are dispensed concurrently with opioid analgesics or benzodiazepines has increased in recent years, with more than half of patients, according to some analyses, concurrently receiving an opioid analgesic. Our continued investigations may underpin future regulatory action to address any harmful trends, and our experience with the opioid crisis has instructed us to act with speed and vigilance when potential new addiction trends emerge. For complete article go to N.E.J.M https://www.nejm.org/doi/full/10.1056/NEJMp1806486?query=psychiatry

 

 

Posted in Uncategorized | Leave a comment

US: Legalizie ‘IT’ and Kids will Come!

For Immediate Release: June 4, 2018
Contact: Colton Grace Colton@learnaboutsam.org (864) 492-6719

 

New Study Finds One in Four 12th Graders More Likely to Use Marijuana If Legalized

Monitoring The Future Study Finds Percentage of 12th Graders Admitting They Would Use Marijuana Reaching Levels Never Before Seen in 43-Year History
[Alexandria , VA ] - More 12th graders than ever admitted they would use marijuana if it were legal, according to new numbers from the largest drug use survey in the United States. Specifically, one in four 12th graders thought that they would try marijuana, or that their use would increase, if marijuana were legalized. Prevalence of annual marijuana use also rose by a significant 1.3 percentage points to 23.9% in 2017, based on data from 8th, 10th, and 12th grades combined. 

The survey reported “a greater proportion of youth than ever predicted they would use marijuana if it were legally available. Historic highs over the 43 years of the study were reached in the percentage of 12th grade students who reported that they would try marijuana if it were legal (15.2%), as well as users who reported that they would use it more often than their current level of use (10.1%). The percentage who reported they would not use marijuana even if it were legal significantly declined to less than 50% for the first time ever over the 43-year life of the study (specifically, to 46.5%).”
Overall, the rate of 12th graders saying they would not use marijuana if it were legalized fell 30% in the last ten years. Additionally, the rate of 12th graders who said they would use more marijuana if it were legal increased by almost 100% in the past decade. These changes are also significant when comparing rates from 2016. Marijuana sales are now allowed in eight states and D.C.
“These findings fly in the face of the Big Marijuana argument that somehow fewer young people will use marijuana if it is legalized,” said Dr. Kevin Sabet, founder and president of Smart Approaches to Marijuana. “These data are clear. As more states move to commercialize, legalize, and normalize marijuana – more young people are going to use today’s super-strength drug.”
The survey reported that “ it is likely that the growing number of states that have legalized recreational marijuana use for adults plays a role in the increasing tolerance of marijuana use among 12th grade students, who may interpret increasing legalization as a sign that marijuana use is safe and state-sanctioned.”
Interestingly, the survey also found that 17% of 12th graders today believe that their parents would not disapprove of marijuana use. This is almost double that of the 8% average from the late 1970′s. 

The 2017 Monitoring the Future survey, compiled by researchers at the University of Michigan and funded by the National Institutes of Health, is the benchmark for student drug use in the United States.
According to the survey, the combination of low levels of perceived risk when it comes to using marijuana and the low disapproval for regular use sets the stage for “potentially substantial” increases in the use of the substance in the future.  In 2017 the proportion of 12th graders who favor legalization of marijuana was at the highest level ever recorded, at 49%.

“This survey confirms what public health advocates have long claimed: as more is done to make THC candies, cookies, sodas, concentrates look innocent and safe, young people are more attracted to them and hold favorable views of them,” said Dr. Sabet. “In states that have loosened their marijuana laws youth use is steadily rising. This is a trend that will continue if we do not pump the brakes on this failed experiment.”

 

Posted in Uncategorized | Leave a comment

USA: Finally Real Cannabis Based Medicine – Time to stop ‘Snake Oil Salesmen’!

For Immediate Release
June 25, 2018  

Contact: Colton Grace  

Colton@learnaboutsam.org    

864-492-6719

SAM Applauds FDA Approval of First CBD Medication

(Alexandria, VA) – Today, Smart Approaches to Marijuana (SAM) founder and president, Dr. Kevin Sabet, released the following statement regarding the recent FDA approval of the first cannabidiol medication, Epidiolex:

“Today, the FDA reached a milestone by approving a pure CBD oil medication – Epidiolex – for the treatment of two rare epileptic disorders. This is an important development. Medication should be left up to science, not political ideology, and now desperately ill patients can access this safe and effective medication through doctors and pharmacies.
“Previous research by the FDA found that many of the oils marketed as CBD contained dangerous substances, including high amounts of THC. Medication development should be left up to scientists and the FDA, not a for-profit marijuana industry that bypasses all regulation.  Today’s decision should be commended.”
FDA Commissioner Scott Gottelib made the following important point in his statement this afternoon: “This is an important medical advance. But it’s also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use.”

 

Posted in Uncategorized | Leave a comment

Global: Ecstasy and alternative to Booze? MDMA Madness!

Why Ecstasy is more harmful than alcohol (whatever Professor Nutt says)

By  Professor Andy Parrott one of the world’s leading experts on MDMA, Andy Parrott, Professor of Human Psychopharmacology, School of Health Sciences, Swansea University.

Comparing alcohol with MDMA.

Alcohol is certainly a damaging drug, but to suggest that MDMA is less damaging than alcohol does not agree with the scientific evidence (Professor Nutt, 21st May). Comparing these two drugs is like comparing an F1 sports car to a basic family saloon. MDMA is an extremely powerful drug, which heats up the brain, causing a massive increase in neurochemical activity, dramatic changes in mood state, and it takes the brain several days to recover. Regular MDMA usage impairs memory, reduces problem-solving ability, reduces white cell blood count, increases susceptibility to infections, causes sleep problems, and enduring depression. In pregnant women MDMA impairs foetal development. We and other research groups worldwide have compared the psychobiological functioning of recreational Ecstasy/MDMA users with alcohol drinkers, and in numerous studies it is always the Ecstasy/MDMA users who are comparatively worse. The ‘family car’ may kill more people each year than the F1 speed machine, but to suggest that the latter would be safer for everyday driving is completely erroneous. MDMA kills many young people each year, and the death toll is currently rising. Yours etc . . .

In the next few paragraphs, I have provided more information on this topic.

What is the basis for Professor Nutt claiming that MDMA is a safer drug than alcohol? This statement was based primarily on a survey he published in the Lancet (Nutt et al, 2007, vol 369; 1047). However this article contains some astounding errors. Indeed when I was first shown it, I contacted the Lancet stating that they needed to publish a detailed reply from me, since it was important to point out these errors. After some email exchanges with one of the Lancet editors, the journal decided not to publish my letter. However I presented some of my criticisms as a conference paper (Parrott, 2009. ‘How harmful is Ecstasy/MDMA: an empirical comparison using the Lancet scale for drug-related harm’. Journal of Psychopharmacology, vol 23, page 41).

I have listed below my main criticisms:

1. Nutt stated that ‘for drugs which have only recently become popular such as Ecstasy or MDMA, the longer term health consequences can only be estimated from animal toxicology at present’. This statement was grossly incorrect. Numerous articles (indeed several hundred) had been published before 2006 by various research groups worldwide, including many papers from my own group. These papers revealed a wide range of adverse health and related problems.

2. One of the Nutt harm scales was ‘intensity of pleasure’, since it is well documented that the most powerful mood enhancers also cause the most problems. Nutt’s article gave heroin and cocaine the maximum scores of 3.0, while nicotine was rated at 2.3, whereas MDMA was given the surprisingly low rating of 1.6. This made MDMA one of the least pleasurable of all their drugs (16th lowest out of their 20 drugs). This low pleasure score for MDMA is simply incomprehensible. How can anyone with even a rudimentary knowledge of human psychopharmacology state that Ecstasy/MDMA is less pleasurable than a cigarette? Yet this low rating was apparently given by Nutt’s group of experts! Recreational Ecstasy/MDMA users would certainly be very surprised at this low rating. It should be noted that this very low ‘pleasure’ score contributed directly to MDMA’s low ‘harm’ score.

3. Drug ‘injection potential’ was another scale, with heroin and cocaine again being given maximum scores of 3.0. In contrast MDMA was given a score of 0.0. This zero score was again bizarre, since MDMA is injected by some heavy users, and they suffer from the problems typically associated with drug injecting. This practice has been noted in various academic papers. Hence the injection score for MDMA should have been similar to that given for cocaine – namely 3.0. The zero score in Nutt et al may be difficult to comprehend, but again it was crucial for generating MDMA’s low overall harm score.

4. In my commentary paper (Parrott, 2009, see above), I provided harm estimates based on the empirical literature, and MDMA rose from 18th to 5th in the list of most damaging drugs. Hence the position of 18th given by Nutt et al in their Lancet paper is extremely misleading – and has no basis in science.

5. So what exactly are the problems caused by MDMA?

6. In 2011 I was asked by the USA Deputy Attorney General to be an expert witness in a court case, which debated the issue of the most appropriate sentences for Ecstasy/MDMA drug traffickers. I was asked to write a comprehensive report, based on all the available scientific research. This was later expanded into a comprehensive review (Parrott, 2013, Neuroscience and Biobehavioral Reviews 37: 1466-1484). The following brief summaries are based on that review, and many of my more recent papers.

7. MDMA is damaging when taken acutely, since it heats up the brain, impairs thermal control, increases neurotransmitter release, and generates extreme mood changes. It also leads to cognitive confusion, and a marked increase in neurohormonal activity. Death rates from acute abreactions are comparatively rare (around 60 per year in the UK), but have been increasing due probably to the increasing levels of MDMA in Ecstasy tablets (see reports by Professor Fabrizio Schifano for the UK, with similar increases reported within mainland Europe).

8. MDMA is also damaging when taken repeatedly. It leads to alterations and/or deficits in brain activity which may be permanent, with reductions in memory ability, reductions in problem-solving skills, deficits in complex visual abilities, impairments in some psychomotor skills, various health impairments, increased levels of depression, increased levels of aggression, and other deficits. Young women should certainly avoid MDMA if there is any possibility of pregnancy – since it can lead to impairments in subsequent child development (Professor Lynn Singer, et al, Neurotoxicology and Teratology, vol 54, pages 22-28).

9. I could go on describing more of the problems caused by MDMA – but will limit myself to one final point. MDMA has been medically tested for cancer therapy, since it can damage/kill human cells. The medical term for this is apoptosis, and it was first demonstrated in laboratory animals, but has subsequently been confirmed in human cells (the relevant medical papers were cited in Parrott, 2013, Human Psychopharmacology, vol 28, pages 289-307).

10. In summary, alcohol is certainly a damaging drug, and when misused it causes massive problems to individual drinkers, their families, and wider society. However the majority of alcohol drinkers are able to use it safely over their lifetimes. In contrast, MDMA is a far more powerful and damaging drug. Current evidence suggest that its regular usage is not only damaging to many young users, but that this damage may endure for several years following drug cessation (Taurah et al, 2013, Psychopharmacology vol 231, pages 737-751).

MDMA Madness

 

Posted in Uncategorized | Leave a comment

Global: Can Cannabis Cure Cancer???

Can cannabis cure cancer?

Of course, it does! Haven’t you heard the rantings of the cannabis quacks! It is not only the cure for cancer, but THE panacea of all ills!

Well, there is no doubt that there is some therapeutic capacity in this complex 400 plus compound and 100 plus cannabinoid containing plant, but decades of trial and research have yielded only a very few symptoms managing potentials – and they too not without potential negative effects!  But hey, let’s not let facts get in the way of a good ‘hope’ generating story… Now that’s not all bad. Hope, not cannabis use maybe the reason why a few people have experienced some relief from use of this plant. It’s interesting to note that perceived benefits on some conditions in some settings, were statistically not better than placebo’s in double blind trials – so hope or ‘faith’ can influence the body as much as a plant compound! Hmmm, but that’s an existential question for another day, not a medical one now.

Just a couple of recent articles…

Eight people’s cancers showed some kind of response to the treatment, and one didn’t respond at all. All the patients died within a year, as might be expected for people with cancer this advanced.

The results from this study show that THC given in this way is safe and doesn’t seem to cause significant side effects. But because this was an early stage trial, without a control group, it’s impossible to say whether THC helped to extend their lives. And while it’s certainly not a cure,  the trial results suggest that cannabinoids are worth pursuing in clinical trials.

There is also a published case report of a 14-year old girl from Canada who was treated with cannabis extracts (also referred to as “hemp oil”), but there is limited information that can be obtained from a single case treated with a varied mixture of cannabinoids. More published examples with detailed data are needed in order to draw a fuller picture of what’s going on. [Updated 26/03/14, KA]

Unverified anecdotes about ‘cures’ do little to help progress towards more effective treatments for patients on a wider scale – even if they do get published in newspapers, they aren’t strong scientific evidence. In order to build a solid evidence base that might support future applications for funding or clinical trials it’s important to gather together detailed information about individual cases. Cannabis Cancer Cure?

Cannabis and Cannabinoids (PDQ®)–Health Professional Version (NIH – Cancer Institute)

Overview: This cancer information summary provides an overview of the use of Cannabis and its components as a treatment for people with cancer-related symptoms caused by the disease itself or its treatment.

This summary contains the following key information:

  • Cannabis has been used for medicinal purposes for thousands of years.
  • By federal law, the possession of Cannabis is illegal in the United States, except within approved research settings; however, a growing number of states, territories, and the District of Columbia have enacted laws to legalize its medical use.
  • The U.S. Food and Drug Administration has not approved Cannabisas a treatment for cancer or any other medical condition.
  • Chemical components of Cannabis, called cannabinoidsactivate specific receptors throughout the body to produce pharmacologic effects, particularly in the central nervous system and the immune system.
  • Commercially available cannabinoids, such as dronabinol and nabilone, are approved drugs for the treatment of cancer-related side effects.
  • Cannabinoids may have benefits in the treatment of cancer-related side effects.

Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the NCI Dictionary of Cancer Terms, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.

Reference citations in some PDQ cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the National Cancer Institute. Cannabis Cancer Cure?

 

Let’s start by asking what the medical efficacy might be. Contrary to what most people believe, medical uses of cannabis have been widely studied. A 2017 review by the National Academy of Science looked at over 10,000 studies. They found evidence for some applications of cannabis, including managing chronic pain and spasms associated with multiple sclerosis. There was also good evidence that tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, can reduce the nausea caused by chemotherapy. Indeed, a synthetic form of THC, called dronabinol, has been prescribed for just this use for decades.

But, crucially, there is zero evidence that cannabis has any curative or even helpful impact on cancer, despite enthusiastic claims to the contrary. Cannabis Cancer Cure?

 

Medicinal cannabis should not be used ahead of approved drugs – German review:

The increasing number of German doctors prescribing cannabis is being fuelled in part by “hype,” concludes a review that contends that in most cases “tried and tested” drugs are better options.

The review says that research into the use of cannabis for medical treatment has been limited, in comparison with the intensive research process before traditional drugs receive regulatory approval. What limited research there is does not support the claims made by proponents medicinal cannabis, it says.

“Cannabis is not a miracle drug,” said the study coauthor Gerd Glaeske, an expert in healthcare economics and policy at the University of Bremen.

The 90 page cannabis report was commissioned by Techniker Krankenkasse (TK),1 one of Germany’s largest public sector health insurers Cannabis Cure Cancer?

 

 

 

Posted in Uncategorized | Leave a comment

UK: Panacea Propaganda Muddles Medicos

Commons doctors rally to false cause over cannabis

By  Kathy Gyngell May 26, 2018

It is a pity the doctors of the House of Commons don’t find time for research. Before rallying to the cause of Alfie Dingley and campaigning ‘to change the law banning the medicinal use of cannabis’ they should have checked the facts. So should the Guardian.

So too should Cathy Newman of Channel 4 News, who also assumes that cannabis-based meds are illegal in the UK.

It simply is not true. The medicinal use of cannabis is not illegal in the UK. Licensed medicines, extracted and purified substances from the cannabis plant have been available for many years.

One of its active ingredients, tetrahydrocannabinol or THC, under the name of Nabilone and now made synthetically, has been around for about 30 years and is used for the relief of nausea resulting from chemotherapy. There are caveats. It is not uniformly well-tolerated and can exacerbate rather than reduce vomiting. Since safer and more efficient medications exist, THC-derived clinical compounds tend to be used only when other interventions have failed.

Sativex, a combination of THC and another ingredient, cannabidiol or CBD, is licensed for the relief of muscle stiffness (spasticity) in patients with multiple sclerosis. Warnings on its use are similarly extensive. Finally CBD is being clinically tested for some types of epilepsy. In the US Epidiolex, a pharmaceutical-grade form of CBD developed by GW Pharmaceuticals, has been approved by the Federal Drug Administration. In the UK the work to clear it is not complete.

For anyone who hasn’t been in Holland and Barrett recently, cannabis oil which contains CBD is available to buy in the UK, subject to the Medicines & Healthcare products
Regulatory Agency (MHRA) statement on products containing CBD. It is not illegal if it contains less than 0.05 per cent THC.

The trouble is that the term ‘cannabis oil’ is dangerously imprecise. The make-up of the cannabis oil Alfie Dingley’s mother says her child needs and which is available to her in the Netherlands has never been specified despite the extensive news coverage of the case. Such misleading and inaccurate reportage raises the question as to its purpose – to lobby for the legalisation of the Class B drug, perhaps?

The bottom line is that even in the upside-down and parallel truths world we live in, there is still such a thing as objective fact. We are, too, still a first world nation with a first world pharmaceutical approval system. It is not foolproof, as the terrible thalidomide tragedy showed us, but such a tragedy is exactly what it is designed to protect us from – and it does.

For complete article https://www.conservativewoman.co.uk/commons-doctors-rally-to-false-cause-over-cannabis/?utm_source=TCW+Daily+Email&utm_campaign=fc81c3811a-RSS_DAILY_EMAIL&utm_medium=email&utm_term=0_a63cca1cc5-fc81c3811a-556077329

 

Posted in Uncategorized | Leave a comment

USA: M.A.C. Babies Latest Attacked by Marijuana Industry

Marijuana Accountability Coalition Takes Action to Defend Babies from the Marijuana Industry

For Immediate Release: 

May 29, 2018 Contact: Justin Luke Riley JLR@MarijuanaAccountability.co 720-401-5500

Marijuana Accountability Coalition Takes Action to Defend Babies from the Marijuana Industry

(Denver, CO) -Today, the Marijuana Accountability Coalition (MAC), in partnership with Smart Approaches to Marijuana (SAM), launched the “Don’t Hurt Our Future” Campaign, holding the marijuana industry accountable for putting money and greed over public safety in pushing products to pregnant mothers and unborn children.

As recently reported, over 70% percent of marijuana dispensaries in Colorado were found to be recommending high-potency THC products to mothers as a remedy for symptoms of morning sickness. According to the Centers for Disease Control, marijuana use during pregnancy could result in low birth weight and other developmental issues in the womb.

In order to keep the marijuana industry from sweeping this under the rug, MAC and SAM are placing 1,000 baby bibs, with the phrase “Don’t Hurt Our Future”, on the doors of marijuana dispensaries, State House offices, and the Colorado Department of Revenue.

“The marijuana industry will stop at nothing to make a buck,” said Justin Luke Riley, founder of the MAC. “Going against all available science, the industry is now recommending pot for pregnant women. They must be held accountable for their actions and not simply be given a slap on the wrist. They are actively putting their profits ahead of the healthy development of future Coloradans.

“The for-profit pot industry must be stopped. We have long known that the marijuana industry has no shame, but this is a new low,” said Dr. Kevin Sabet, founder and president of SAM. “We demand that Colorado state government take immediate action and stop the pot industry from continuing with this. Pot and pregnancy don’t mix.”

www.MarijuanaAccountability.co

 

 

Posted in Uncategorized | Leave a comment